Vir Biotechnology, Inc.
VIR
$5.09
-$0.325-6.01%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -75.50% | 419.92% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -75.50% | 419.92% | |||
| Cost of Revenue | 32.47% | -54.52% | |||
| Gross Profit | -49.95% | 60.38% | |||
| SG&A Expenses | -10.33% | 3.72% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 22.57% | -47.74% | |||
| Operating Income | -34.34% | 52.83% | |||
| Income Before Tax | -15.55% | 50.98% | |||
| Income Tax Expenses | 118.60% | -148.59% | |||
| Earnings from Continuing Operations | -15.66% | 51.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.66% | 51.06% | |||
| EBIT | -34.34% | 52.83% | |||
| EBITDA | -35.35% | 53.53% | |||
| EPS Basic | -15.09% | 51.12% | |||
| Normalized Basic EPS | -40.52% | 55.75% | |||
| EPS Diluted | -15.09% | 51.12% | |||
| Normalized Diluted EPS | -40.52% | 55.75% | |||
| Average Basic Shares Outstanding | 0.48% | 0.11% | |||
| Average Diluted Shares Outstanding | 0.48% | 0.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||